Skip to main content

Table 3 Relative risk for progression to cancer

From: Breast cancer risk in papilloma patients: Osteopontin splice variants indicate prognosis

Ipsilateral

Contralateral

 

Comparison

Relative Risk

CI (95%)

 

p value Fisher

p value χ2

 

Comparison

Relative risk

CI (95%)

 

p value Fisher

p value χ2

OPN-c

OPN-c

 Intensity

H/L

4.043

1.159

14.109

0.027

0.016

 Intensity

H/L

7.143

0.866

58.946

0.079

0.031

 Positivity

H/L

4.484

0.651

35.970

0.101

0.008

 Positivity

H/L

1.000

0.193

5.190

1.000

1.000

 Additive

(I + H)/L

4.231

0.571

31.366

0.173

0.111

 Additive

(I + H)/L

2.083

0.254

17.087

0.668

0.480

 

H/I

3.663

0.846

15.863

0.099

0.055

 

H/I

(0.128)

  

0.058

0.033

OPN ex4

OPN ex4

 Intensity

H/L

1.623

0.556

4.743

0.507

0.375

 Intensity

H/L

1.200

0.232

6.205

1.000

0.828

 Positivity

H/L

0.769

0.260

2.274

0.763

0.634

 Positivity

H/L

4.808

0.582

39.703

0.205

0.102

 Additive

(I + H)/L

0.862

0.297

2.504

1.000

0.785

 Additive

(I + H)/L

3.947

0.478

32.597

0.225

0.163

 

H/I

2.296

0.456

11.569

0.402

0.297

 

H/I

0.853

0.154

4.228

1.000

0.855

Combined

Combined

 Intensity

(I + H)/L

(0.182)

  

0.003

0.003

 Intensity

(I + H)/L

3.644

0.441

30.080

0.397

0.192

 

H/I

0.680

0.167

2.771

0.719

0.580

 

H/I

1.956

0.036

10.603

0.593

0.434

 Positivity

(I + H)/L

(0.136)

  

0.118

0.580

 Positivity

(I + H)/L

(0.073)

  

0.595

0.434

 

H/I

0.689

0.224

2.119

0.754

0.511

 

H/I

1.278

0.274

5.959

1.000

0.755

  1. The relative risk for progression was calculated for the ipsilateral (left block) or contralateral (right block) breast. The pathology scores were condensed to 0,1 = low (L) and 2,3 = high (H). Then, an additive score was derived as intensity plus percent positivity with low = both components low, intermediate (I) = one low and the other high, high = both high. hOPNc additive = additive score for staining with anti-OPNc antibody F2, hOPNex4 additive = additive score for staining with anti-exon 4 antibody MAP193P. A combined score was derived from the additive scores for both antibodies, such that low/low and low/intermediate were combined to low, low/high and intermediate/intermediate were combined to intermediate, and intermediate/high and high/high are combined to high. CI (95%) = 95% confidence interval, Fisher indicates Fisher’s exact test, c2 = c2 test. Numbers in parentheses indicate the risk for the higher pathology score alone (relative risk could not be calculated because of a division by 0 error)
Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us